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Supplementary Tables 1 and 2 are omitted from the Supplementary Information which accompanies this Article. Tables [S1](#Tab1){ref-type="table"} and [S2](#Tab2){ref-type="table"} appear below.Table S1Demographic details of cohorts of HBs^lo^ and HBs^hi^ CHB patients and healthy subjects.CHB (HBs^lo^)CHB (HBs^hi^)healthy donors (HD)Serum HBsAg levels(IU/ml)\<500\<50,000N/Anumber of subjects231610median age (years)(range)54(31--80)35(26--60)37(63--27)Gender(M/F)20/312/46/4Ethnicity(Asian/African/Caucasian)15/5/35/11/02/0/8HBV DNA (log IU/ml)(mean ± SD)2.07 ± 1.044.43 ± 2.36N/AHBeAg(-ve/+ve/UA)20/2/112/4/0N/Aanti-HBeAb(-ve/+ve/UA)5/14/45/6/5N/Amedian ALT (U/L)(range)31.0(9.0--542.0)41.0(14.0--536.0)N/Amedian AST (U/L)(range)26.0(15.0--430.0)39.5(17.0--259.0)N/ASD: standard deviation, UA: Unavailable, ALT: alanine transaminase, AST: aspartate transaminase, N/A: Not applicable.Table S2Details of subjects in second cohort of CHB patients.CHB\
HBsAg \<100 IU/mlCHB\
HBsAg \>5,000 IU/mlnumber of subjects238median age (years)(range)52(34--71)52(39--72)Gender(M/F)15/84/4HBeAg(-ve/+ve/UA)14/1/81/1/6UA: Unavailable.
